Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Harrisburg Wellness Reporter.
Press releases published on April 2, 2025
Nice Healthcare Partners with Business Health Trust to Expand in Washington
GlobeNewswire
·
April 2, 2025
MINNEAPOLIS, April 02, 2025 (GLOBE NEWSWIRE) -- Employers know that offering the right benefits isn’t just about staying competitive—it’s about ensuring their employees have access to the care they need. Nice Healthcare, the clinic that comes to you, is …
Hint Health Announces Hint Summit 2025 at RosettaFest, Uniting DPC with the Future of Healthcare
GlobeNewswire
·
April 2, 2025
SAN FRANCISCO, Calif, April 02, 2025 (GLOBE NEWSWIRE) -- Hint Summit is back—and more connected than ever! This year, Hint Health is taking its flagship event to the next level, bringing Hint Summit 2025 to RosettaFest August 24-27 at the Colorado …
Hydreight Technologies Named One of the Americas’ Fastest Growing Companies by Financial Times
GlobeNewswire
·
April 2, 2025
VANCOUVER, British Columbia and LAS VEGAS, April 02, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing digital health platform transforming mobile and telehealth services in the U.S., has been named …
Prime Biome Reviews DON’T SKIP UNTIL SEE THIS for Preventing Fraud and Guaranteeing Reliability!
GlobeNewswire
·
April 2, 2025
ST. PETERSBURG, Fla., April 02, 2025 (GLOBE NEWSWIRE) -- 2025, a popular supplement for reviving the gut and skin micro biota, Prime Biome has swept the wellness industry. Prime Biome is the greatest option for safe, healthy skin out of all the products …
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 2, 2025
IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham …
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
GlobeNewswire
·
April 2, 2025
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) …
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
GlobeNewswire
·
April 2, 2025
HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the …
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 2, 2025
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that …
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
GlobeNewswire
·
April 2, 2025
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases …
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
GlobeNewswire
·
April 2, 2025
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: …
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
GlobeNewswire
·
April 2, 2025
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported …
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
GlobeNewswire
·
April 2, 2025
Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026 Alignment through recent interactions with CDER on path to accelerated approval and conversion to full approval …
Immunocore to present at upcoming investor conferences
GlobeNewswire
·
April 2, 2025
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England …
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities
GlobeNewswire
·
April 2, 2025
Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput …
MUHC Foundation celebrates $200M Dream Big campaign milestone
GlobeNewswire
·
April 2, 2025
MONTREAL, April 02, 2025 (GLOBE NEWSWIRE) -- The McGill University Health Centre (MUHC) Foundation is proud to announce the successful completion of its ambitious Dream Big campaign, which has surpassed its $200 million fundraising goal. Launched in 2020 …
La campagne Oser rêver de la Fondation du CUSM franchit son objectif de 200 millions de dollars
GlobeNewswire
·
April 2, 2025
MONTRÉAL, 02 avr. 2025 (GLOBE NEWSWIRE) -- La Fondation du Centre universitaire de santé McGill (CUSM) est fière d’annoncer que son ambitieuse campagne Oser rêver a dépassé son objectif de financement de 200 millions de dollars. Lancée en 2020 durant une …
Immutep to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 2, 2025
SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and …
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
GlobeNewswire
·
April 2, 2025
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has …
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
GlobeNewswire
·
April 2, 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
GlobeNewswire
·
April 2, 2025
WAYNE, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from …